Clinical Trials in the EU / 2025-523342-27-00
Authorised, recruiting
Phase II
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata
2025-523342-27-00 · tracked via the Priya Life Science EU tracker
Condition studied
Alopecia areata
Investigational medicinal product(s)
Placebo for LAD603LAD603
Eligibility
Primary endpoint
Percent change from baseline in the SALT score, at Week 36.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-523342-27-00 on CTIS ↗ ← All trials in the EU